Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz

Ítems similars

• Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
  per: Chetty, Manoranjenni, et al.
  Publicat: (2014)
• Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
  per: Chetty, Manoranjenni, et al.
  Publicat: (2015)
• Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site
  per: Musther, Helen, et al.
  Publicat: (2015)
• Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model
  per: Abduljalil, Khaled, et al.
  Publicat: (2014)
• Prediction of the pharmacokinetics, pharmacodynamics and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model.
  per: Manoranjenni eChetty, et al.
  Publicat: (2015-01-01)